Optimized Duration of Clopidogrel Therapy Following Treatment With the Endeavor - Optimize Trial
Status:
Completed
Trial end date:
2015-07-01
Target enrollment:
Participant gender:
Summary
Prospective, multicenter, randomized (two-arm 1:1), non-inferiority clinical evaluation
comparing 2 regimes of dual antiplatelet therapy (DAPT) with aspirin + clopidogrel following
percutaneous coronary intervention (PCI) with Endeavor Zotarolimus eluting stent (ZES) to
evaluate the impact of different regimes of DAPT on clinical outcomes in minimally selected
patients from the "real-world" clinical practice receiving the Endeavor ZES for the treatment
of coronary artery lesions. Patients undergoing percutaneous treatment with the Endeavor ZES
will be randomized in a 1:1 ratio to 2 regimens of DAPT including oral clopidogrel 75mg/day
for 3 months versus 12 months.